Related Experiment Video
Updated: May 4, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
8.3K
[Anti-diabetes agents and hypoglycemia]
Giornale Italiano Di Cardiologia (2006)
|December 24, 2013
Summary
Choosing type 2 diabetes treatments requires careful consideration of hypoglycemia risk. Metformin, thiazolidinediones, and newer therapies like incretin-based drugs have low risks, unlike sulfonylureas.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Hypoglycemia is a major concern in managing type 2 diabetes.
- Limited data exists on drug-specific hypoglycemia frequencies.
- Interpreting existing data is challenging due to varied collection methods and definitions.
Purpose of the Study:
- To evaluate the hypoglycemia risk associated with different type 2 diabetes medications.
- To inform therapeutic strategy selection based on iatrogenic hypoglycemia potential.
Main Methods:
- Review of available literature on hypoglycemia incidence with various antidiabetic drugs.
- Comparative analysis of hypoglycemia risk across drug classes.
Main Results:
- Metformin and thiazolidinediones demonstrate negligible hypoglycemia risk.
- Sulfonylureas, especially glybenclamide, are associated with higher-than-expected hypoglycemia frequency.
- Incretin-based therapies show a very low hypoglycemia risk, increasing significantly only when combined with insulin or sulfonylureas.
Conclusions:
- Therapeutic choices for type 2 diabetes must prioritize minimizing hypoglycemia risk.
- Metformin, thiazolidinediones, and incretin-based therapies are favorable options regarding hypoglycemia.
- Caution is advised when using sulfonylureas due to their significant hypoglycemia potential.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
953
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:26Hypoglycemia
30
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
30
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K